AI Article Synopsis
- Celastrol is a compound with multiple therapeutic functions, including anti-inflammation, and has been used to treat various conditions like rheumatism and skin diseases.
- A study on Celastrol's effects on glucocorticoid-induced osteoporosis (GIOP) in rats showed it reduced several markers of bone degradation and stimulated bone formation.
- The research indicates that Celastrol's protective effects against GIOP may involve the PI3K/AKT and Wnt signaling pathways, highlighting its potential as a treatment for osteoporosis.
Article Abstract
Modern pharmacological studies revealed that Celastrol exhibits anti‑inflammation, anti‑bacteria, anti‑virus, anti‑fertility, insect‑resistance functions and has been used for the treatment of rheumatism, rheumatoid arthritis, blood diseases, skin diseases and agricultural insecticide. The present study aimed to investigate the effects of Celastrol on glucocorticoid‑induced osteoporosis (GIOP) and the underlying molecular mechanisms. The findings of the current study revealed that Celastrol reduced body weight, urine calcium/creatinine, tartrate‑resistant acid phosphatase 5b, C‑terminal telopeptide of type I collagen, and induced osteocalcin in GIOP rats. In addition, alkaline phosphatase, triiodothyronine receptor auxiliary protein and cathepsin K mRNA expression levels were effectively suppressed, and osteocalcin, bone morphogenetic protein 2, type I collagen and runt‑related transcription factor 2 mRNA expression levels were effectively induced in osteoporosis rats treated with Celastrol. Celastrol inhibited prostaglandin E2 and caspase‑3 protein expression levels, and induced phosphoinositol 3‑kinase (PI3K), phosphorylated‑protein kinase B (AKT) and glycogen synthase kinase‑3 phosphorylation, Wnt and β‑catenin protein expression in GIOP rats. The present study demonstrated that Celastrol may inhibit GIOP in rats via the PI3K/AKT and Wnt signaling pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/mmr.2018.9436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ED-71 promotes osseointegration of titanium implants in a rat model of GIOP by alleviating the effects of dexamethasone on bone remodeling in a SIRT1-dependent manner.
J Oral Biosci
October 2024
Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, China.
Article Synopsis
- Glucocorticoid-induced osteoporosis (GIOP) complicates dental implant success, and the study investigates the role of Eldecalcitol (ED-71) in improving osseointegration under such conditions.
- A rat model of GIOP was used, with mini-implants surgically placed, while ED-71 was administered to examine its effect on bone remodeling and implant integration.
- Results showed that ED-71 enhanced new bone formation and reduced inflammation around implants, working through the sirtuin 1 (SIRT1) pathway and affecting key signaling pathways related to bone health.
Anti-inflammatory, antiosteoporotic, and bone protective effect of hydroxysafflor yellow A against glucocorticoid-induced osteoporosis in rats.
J Biochem Mol Toxicol
September 2024
Department of Orthopedics, Shandong Public Health Clinical Center, Shandong University, Jinan, China.
Osteoporosis is a common condition worldwide, affecting millions of people. Women are more commonly affected than men, and the risk increases with age. Inflammatory reaction plays a crucial role in the expansion of osteoporosis.
View Article and Find Full Text PDFDendrobine Ameliorates Glucocorticoid-Induced Osteoporosis by Promoting Osteogenesis through JNK/p38 MAPK Pathway Activation and GR Nuclear Translocation Inhibition.
J Agric Food Chem
July 2024
Department of Orthopedics, the First Affiliated Hospital of Jishou University, Jishou 416000, Hunan, China.
Glucocorticoid-induced osteoporosis (GIOP) is the common reason for secondary osteoporosis. Dendrobine (DEN) is the major biologically active component of with anti-inflammatory and antiaging properties. Whether DEN could alleviate osteogenic inhibition in GIOP rats is still unknown.
View Article and Find Full Text PDFAlleviation of Glucocorticoid-Induced Osteoporosis in Rats by Ethanolic (Thunb.) Moldenke Extract.
J Med Food
April 2024
Guangdong Key Laboratory for Research and Development of Natural Drug, Department of Pharmacology, Guangdong Medical University, Zhanjiang, China.
Secondary osteoporosis is frequently due to the use of high-dose glucocorticoids (GCs). The existing strategy for managing glucocorticoid-induced osteoporosis (GIOP) is considered insufficient and remains in a state of ongoing evolution. Therefore, it is crucial to develop more precise and effective agents for the treatment of GIOP.
View Article and Find Full Text PDFattenuates glucocorticoid-induced osteoporosis by altering the composition of rat gut microbiota and serum metabolic profile.
Front Immunol
January 2024
The Orthopaedic Center, The First People's Hospital of Wenling, Wenling Hospital of Wenzhou Medical University, Wenling, Zhejiang, China.
Introduction: Osteoporosis, one of the most common non-communicable human diseases worldwide, is one of the most prevalent disease of the adult skeleton. Glucocorticoid-induced osteoporosis(GIOP) is the foremost form of secondary osteoporosis, extensively researched due to its prevalence.Probiotics constitute a primary bioactive component within numerous foods, offering promise as a potential biological intervention for preventing and treating osteoporosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!